Halozyme Therapeutics (HALO) Tops Q1 EPS by 4c; FY Revenue Guidance Tops Views
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $80.37 -1.47%
Revenue Growth %: +23.1%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +23.1%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.16), $0.04 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $42.5 million versus the consensus estimate of $29.65 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $130-145 million, versus the consensus of $127.89 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
- Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
- Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
